Inhibition of in-stent stenosis by oral administration of bindarit in porcine coronary arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 11, 2011, Pages 2448-2454

  Ialenti, Armando ^a   Grassia, Gianluca ^a   Gordon, Peter ^b,c   Maddaluno, Marcella ^a   Di Lauro, Maria Vittoria ^a   Baker, Andrew H ^c   Guglielmotti, Angelo ^d   Colombo, Antonio ^e   Biondi, Giuseppe ^d   Kennedy, Simon ^c   Maffia, Pasquale ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d Università Politecnica delle Marche ACRAF Gruppo Angelini   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

bindarit; pharmacology; restenosis; stent

Indexed keywords

ACETYLSALICYLIC ACID; BINDARIT; CLOPIDOGREL; HEPARIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; EUTHANASIA; MACROPHAGE; MALE; MONOCYTE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; STENT THROMBOSIS; SWINE;

ADMINISTRATION, ORAL; ANIMALS; CELL PROLIFERATION; CORONARY STENOSIS; CORONARY VESSELS; INDAZOLES; MALE; MODELS, ANIMAL; MONOCYTE CHEMOATTRACTANT PROTEINS; MUSCLE, SMOOTH, VASCULAR; NEOINTIMA; PROPIONIC ACIDS; STENTS; SWINE; TREATMENT OUTCOME;

EID: 80054936616     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.230078     Document Type: Article

References (32)

1. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28:1950-1959.
2. Selzman CH, Miller SA, Zimmerman MA, Gamboni-Robertson F, Harken AH, Banerjee A. Monocyte chemotactic protein-1 directly induces human vascular smooth muscle proliferation. Am J Physiol Heart Circ Physiol. 2002;283:H1455-H1461.
3. Parenti A, Bellik L, Brogelli L, Filippi S, Ledda F. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;286:H1978-H1984. (Pubitemid 38525489)
4. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, Matsushima K, Sasayama S. Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res. 1999;84:306-314. (Pubitemid 29095571)
5. Egashira K, Koyanagi M, Kitamoto S, Ni W, Kataoka C, Morishita R, Kaneda Y, Akiyama C, Nishida KI, Sueishi K, Takeshita A. Antimonocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J. 2000;14:1974-1978.
6. Egashira K, Nakano K, Ohtani K, Funakoshi K, Zhao G, Ihara Y, Koga J, Kimura S, Tominaga R, Sunagawa K. Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol. 2007;27: 2563-2568. (Pubitemid 350158906)
7. Horvath C, Welt FG, Nedelman M, Rao P, Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res. 2002;90:488-494. (Pubitemid 34633920)
8. Nakano K, Egashira K, Ohtani K, Zhao G, Funakoshi K, Ihara Y, Sunagawa K. Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis. 2007;194:309-316. (Pubitemid 47513092)
9. Mirolo M, Fabbri M, Sironi M, Vecchi A, Guglielmotti A, Mangano G, Biondi G, Locati M, Mantovani A. Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins. Eur Cytokine Netw. 2008;19:119-122.
10. Perico N, Benigni A, Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7:936-853.
11. Rulli NE, Guglielmotti A, Mangano G, Rolph MS, Apicella C, Zaid A, Suhrbier A, Mahalingam S. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum. 2009;60:2513-2523.
12. Bhatia M, Devi Ramnath RD, Chevali L, Guglielmotti A. Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis. Am JPhysiol Gastrointest Liver Physiol. 2005;288: G1259-G1265. (Pubitemid 40741080)
13. Bhatia M, Landolfi C, Basta F, Bovi G, Ramnath RD, de Joannon AC, Guglielmotti A. Treatment with bindarit, an inhibitor of MCP-1 synthesis, protects mice against trinitrobenzene sulfonic acid-induced colitis. Inflamm Res. 2008;57:464-471.
14. Lin J, Zhu X, Chade AR, Jordan KL, Lavi R, Daghini E, Gibson ME, Guglielmotti A, Lerman A, Lerman LO. Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension. Arterioscler Thromb Vasc Biol. 2009;29: 1810-1816.
15. Zhu XY, Chade AR, Krier JD, Daghini E, Lavi R, Guglielmotti A, Lerman A, Lerman LO. The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens. 2009;27:2063-2073.
16. Guglielmotti A, Orticelli G, Di Loreto G, Paolo D. Bindarit decreases monocyte chemoattractant protein-1 urinary excretion in humans: a pilot study in active lupus nephritis patients. Inflammation Res. 2009;58:S169 [Abstract].
17. Grassia G, Maddaluno M, Guglielmotti A, Mangano G, Biondi G, Maffia P, Ialenti A. The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res. 2009; 84:485-493.
18. Johnson GJ, Griggs TR, Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis: analysis and recommendations. On behalf of the Subcommittee on Animal, Cellular and Molecular Models of Thromb Haemost of the Scientific and Standardization Committee of the International Society on Thromb Haemost. Thromb Haemost. 1999;81:835-843.
19. Jeremy JY, Thomas AC. Animal models for studying neointima formation. Curr Vasc Pharmacol. 2010;8:198-219.
20. Touchard AG, Schwartz RS. Preclinical restenosis models: challenges and successes. Toxicol Pathol. 2006;34:11-18.
21. Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int. 1998; 53:726-734. (Pubitemid 28124289)
22. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001; 104:1188-1193. (Pubitemid 32830406)
23. Gunn J, Arnold N, Chan KH, Shepherd L, Cumberland DC, Crossman DC. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart. 2002;88:401-405.
24. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224-230. (Pubitemid 28064746)
25. Work LM, McPhaden AR, Pyne NJ, Pyne S, Wadsworth RM, Wainwright CL. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation. 2001;104:1538-1543. (Pubitemid 32917348)
26. Kasai T, Miyauchi K, Yokoyama T, Kajimoto K, Sumiyoshi K, Kubota N, Ikeda E, Daida H. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis. 2008;197:612-619. (Pubitemid 351417907)
27. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-2295. (Pubitemid 32433720)
28. Chieffo A, Foglieni C, Nodari RL, Briguori C, Sangiorgi G, Latib A, Montorfano M, Airoldi F, Michev I, Carlino M, Colombo A, Maseri A. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. Am J Cardiol. 2009;104:1660-1667.
29. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767-801. (Pubitemid 38823766)
30. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327-334. (Pubitemid 32199112)
31. Guglielmotti A, Orticelli G, Di Loreto G, Paolo D. Bindarit decreases monocyte chemoattractant protein-1 urinary excretion in humans. A pilot study in active lupus nephritis patients. Inflamm Res. 2009;(suppl 2),58:S169 [Abstract].
32. Ruggenenti P. Effects of MCP-1 inhibition by bindarit therapy in type 2 diabetes subjects with micro-or macro-albuminuria. J Am Soc Nephrol. 2009;21:44A [Abstract].